Merck & Co., Inc. (ETR:6MK)

Germany flag Germany · Delayed Price · Currency is EUR
71.90
-0.70 (-0.96%)
Oct 17, 2025, 5:35 PM CET
-0.96%
Market Cap179.60B
Revenue (ttm)54.17B
Net Income (ttm)13.97B
Shares Outn/a
EPS (ttm)5.52
PE Ratio12.86
Forward PE9.36
Dividend2.91 (4.05%)
Ex-Dividend DateSep 15, 2025
Volume3,685
Average Volume4,162
Open71.50
Previous Close72.60
Day's Range71.00 - 72.00
52-Week Range65.50 - 102.00
Beta0.37
RSI45.81
Earnings DateOct 30, 2025

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]

Sector Healthcare
Founded 1891
Employees 75,000
Stock Exchange Deutsche Börse Xetra
Ticker Symbol 6MK
Full Company Profile

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD Financial Statements

News

Merck (MRK) Achieves Key Survival Milestone in Ovarian Cancer Trial

Merck (MRK) Achieves Key Survival Milestone in Ovarian Cancer Trial

1 day ago - GuruFocus

Is Trending Stock Merck & Co., Inc. (MRK) a Buy Now?

Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

1 day ago - Nasdaq

Merck: Earnings Outlook Steady, Keytruda Now Has Some Breathing Room

Merck leads U.S. pharma in 2025, but faces Keytruda patent loss by 2028. Click for my look at MRK stock ahead of its upcoming Q3 earnings release.

1 day ago - Seeking Alpha

Merck Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients With Platinum-Resistant Recurrent Ovarian Cancer

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, met ...

1 day ago - Business Wire

Germany's Merck Sets Out Midterm Sales Growth, Profitability Expansion Targets

The company confirmed its 2025 guidance and is targeting annual organic sales growth in the mid-single-digit percentage range and an expansion in profitability over the medium term.

1 day ago - WSJ

Germany's Merck tweaks mid-term healthcare unit guidance

German pharmaceuticals and technology company Merck KGaA slightly improved its mid-term guidance for its healthcare business ahead of its capital markets day on Thursday.

1 day ago - Reuters

Merck: A Golden Buying Opportunity

1 day ago - Seeking Alpha

See Which Of The Latest 13F Filers Holds MRK

At Holdings Channel, we have reviewed the latest batch of the 22 most recent 13F filings for the 09/30/2025 reporting period, and noticed that Merck & Co Inc (Symbol: MRK) was held by 13 of these fund...

2 days ago - Nasdaq

Merck (MRK) Reports Positive Outcomes for New HIV-1 Treatment

Merck (MRK) Reports Positive Outcomes for New HIV-1 Treatment

2 days ago - GuruFocus

Merck's New HIV Treatment Works As Well As Top Drug In Late Trials

The relentless pursuit of innovative treatments in the pharmaceutical industry continues to reshape the landscape of chronic disease management. Merck & Co. Inc. (NYSE: MRK) on Wednesday announced ad...

2 days ago - Benzinga

Merck's New HIV Treatment Works As Well As Top Drug In Late Trials

The relentless pursuit of innovative treatments in the pharmaceutical industry continues to reshape the landscape of chronic disease management. Merck & Co. Inc. (NYSE:MRK) on Wednesday announced addi...

2 days ago - Benzinga

Merck (MRK) Presents Positive Data from HIV-1 Treatment Trials

Merck (MRK) Presents Positive Data from HIV-1 Treatment Trials

2 days ago - GuruFocus

Merck to Acquire the Chromatography Business of JSR Life Sciences, Expanding Protein A Capabilities and Downstream Portfolio

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced the signing of a definitive agreement to acquire the chromatography business of JSR Life Sciences,...

2 days ago - Business Wire

Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the presentation of additional data from the Phase 3 studies of th...

2 days ago - Business Wire

Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential

Shah Capital is reportedly pressing Novavax Inc. (NASDAQ: NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine . • NVAX stock is showing exc...

3 days ago - Benzinga

Can $10,000 in Merck Stock Turn Into $50,000 by 2030?

The pharmaceutical giant has seen brighter days.

3 days ago - The Motley Fool

Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?

Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

4 days ago - Nasdaq

Merck (MRK) Receives Neutral Rating from Citi with Price Target Boost

Merck (MRK) Receives Neutral Rating from Citi with Price Target Boost

4 days ago - GuruFocus

Biotech Stocks Have Struggled Since 2021. Why They're Coming Back.

Too many questionable start-ups went public during the pandemic, when the sector was hot. Now, after over four years of pain, the weak have failed, rates are falling, and M&A looks to be on the upswin...

6 days ago - Barrons

High Margins, Lower Price: Is This Merck Stock's Buying Window?

Merck (MRK) stock merits your attention. Why? Because it offers monopoly-like high margins at a discounted price.

7 days ago - Forbes

Behind the Scenes of Merck & Co's Latest Options Trends

Investors with a lot of money to spend have taken a bearish stance on Merck & Co (NYSE: MRK). And retail traders should know. We noticed this today when the positions showed up on publicly available ...

8 days ago - Benzinga

Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that it will present new findings from its HIV treatment and prevention pipeline at the 20th European AIDS Conf...

8 days ago - Wallstreet:Online